BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and antiproliferative evaluation of fluorenone analogs with DNA topoisomerase I inhibitory properties. 2013

Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan; School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan.

A series of 2,7-diamidofluorenones were designed, synthesized, and screened by SRB assay. Some synthesized compounds exhibited antitumor activities in submicromolar range. Ten compounds (3a, 3b, 3c, 3g, 3j, 3l, 4a, 4h, 4i, and 4j) were also selected by NCI screening system and 3c (GI50=1.66 μM) appeared to be the most active agent of this series. Furthermore, 3c attenuated topoisomerase I-mediated DNA relaxation at low micromolar concentrations. These results indicated that fluorenones have potential to be further developed into anticancer drugs.

UI MeSH Term Description Entries
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013994 Tilorone An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions. Amyxin,Bis-DEAE-Fluorenone,Amiksin,Amixin,Tilorone Hydrochloride,Bis DEAE Fluorenone,Hydrochloride, Tilorone
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D059004 Topoisomerase I Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE I. DNA Topoisomerase I Inhibitor,DNA Topoisomerase III Inhibitor,DNA Topoisomerase III Inhibitors,DNA Type 1 Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitors,Topoisomerase 1 Inhibitor,Topoisomerase 1 Inhibitors,Topoisomerase 3 Inhibitor,Topoisomerase 3 Inhibitors,Topoisomerase I Inhibitor,Topoisomerase III Inhibitor,Topoisomerase III Inhibitors,DNA Topoisomerase I Inhibitors,DNA Type 1 Topoisomerase Inhibitors,1 Inhibitor, Topoisomerase,3 Inhibitor, Topoisomerase,3 Inhibitors, Topoisomerase,I Inhibitor, Topoisomerase,III Inhibitor, Topoisomerase,III Inhibitors, Topoisomerase,Inhibitor, Topoisomerase 1,Inhibitor, Topoisomerase 3,Inhibitor, Topoisomerase I,Inhibitor, Topoisomerase III,Inhibitors, Topoisomerase 1,Inhibitors, Topoisomerase 3,Inhibitors, Topoisomerase I,Inhibitors, Topoisomerase III

Related Publications

Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Rational design, synthesis, biophysical and antiproliferative evaluation of fluorenone derivatives with DNA G-quadruplex binding properties.
April 2010, ChemMedChem,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs.
March 1995, Journal of medicinal chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives.
November 2003, Bioorganic & medicinal chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Synthesis and Topoisomerase I inhibitory properties of klavuzon derivatives.
April 2017, Bioorganic chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Synthesis and topoisomerase I inhibitory properties of luotonin A analogues.
December 2004, Bioorganic & medicinal chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
August 2012, European journal of medicinal chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Design, synthesis, and evaluation of DNA topoisomerase II-targeted nucleosides.
August 2017, Bioorganic & medicinal chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
April 2016, Bioorganic & medicinal chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Antileishmanial activity evaluation of bis-lawsone analogs and DNA topoisomerase-I inhibition studies.
April 2014, Journal of enzyme inhibition and medicinal chemistry,
Chia-Chung Lee, and Deh-Ming Chang, and Kuo-Feng Huang, and Chun-Liang Chen, and Tsung-Chih Chen, and Yang Lo, and Jih-Hwa Guh, and Hsu-Shan Huang
Naphthazarin derivatives (VIII): Synthesis, inhibitory effect on DNA topoisomerase-I, and antiproliferative activity of 6-(1-acyloxyalkyl)-5,8-dimethoxy-1,4-naphthoquinones.
October 2001, Archiv der Pharmazie,
Copied contents to your clipboard!